Suppr超能文献

急性缺血性脑卒中的血管内血栓切除术:一项荟萃分析。

Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis.

机构信息

Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada.

Division of Neurosurgery, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.

出版信息

JAMA. 2015 Nov 3;314(17):1832-43. doi: 10.1001/jama.2015.13767.

Abstract

IMPORTANCE

Endovascular intervention for acute ischemic stroke improves revascularization. But trials examining endovascular therapy yielded variable functional outcomes, and the effect of endovascular intervention among subgroups needs better definition.

OBJECTIVE

To examine the association between endovascular mechanical thrombectomy and clinical outcomes among patients with acute ischemic stroke.

DATA SOURCES

We systematically searched MEDLINE, EMBASE, CINAHL, Google Scholar, and the Cochrane Library without language restriction through August 2015.

STUDY SELECTION

Eligible studies were randomized clinical trials of endovascular therapy with mechanical thrombectomy vs standard medical care, which includes the use of intravenous tissue plasminogen activator (tPA).

DATA EXTRACTION AND SYNTHESIS

Independent reviewers evaluated the quality of studies and abstracted the data. We calculated odds ratios (ORs) and 95% CIs for all outcomes using random-effects meta-analyses and performed subgroup and sensitivity analyses to examine whether certain imaging, patient, treatment, or study characteristics were associated with improved functional outcome. The strength of the evidence was examined for all outcomes using the GRADE method.

MAIN OUTCOMES AND MEASURES

Ordinal improvement across modified Rankin scale (mRS) scores at 90 days, functional independence (mRS score, 0-2), angiographic revascularization at 24 hours, symptomatic intracranial hemorrhage within 90 days, and all-cause mortality at 90 days.

RESULTS

Data were included from 8 trials involving 2423 patients (mean [SD] age, 67.4 [14.4] years; 1131 [46.7%] women), including 1313 who underwent endovascular thrombectomy and 1110 who received standard medical care with tPA. In a meta-analysis of these trials, endovascular therapy was associated with a significant proportional treatment benefit across mRS scores (OR, 1.56; 95% CI, 1.14-2.13; P = .005). Functional independence at 90 days (mRS score, 0-2) occurred among 557 of 1293 patients (44.6%; 95% CI, 36.6%-52.8%) in the endovascular therapy group vs 351 of 1094 patients (31.8%; 95% CI, 24.6%-40.0%) in the standard medical care group (risk difference, 12%; 95% CI, 3.8%-20.3%; OR, 1.71; 95% CI, 1.18-2.49; P = .005). Compared with standard medical care, endovascular thrombectomy was associated with significantly higher rates of angiographic revascularization at 24 hours (75.8% vs 34.1%; OR, 6.49; 95% CI, 4.79-8.79; P < .001) but no significant difference in rates of symptomatic intracranial hemorrhage within 90 days (70 events [5.7%] vs 53 events [5.1%]; OR, 1.12; 95% CI, 0.77-1.63; P = .56) or all-cause mortality at 90 days (218 deaths [15.8%] vs 201 deaths [17.8%]; OR, 0.87; 95% CI, 0.68-1.12; P = .27).

CONCLUSIONS AND RELEVANCE

Among patients with acute ischemic stroke, endovascular therapy with mechanical thrombectomy vs standard medical care with tPA was associated with improved functional outcomes and higher rates of angiographic revascularization, but no significant difference in symptomatic intracranial hemorrhage or all-cause mortality at 90 days.

摘要

重要性

急性缺血性脑卒中的血管内介入治疗可改善血管再通。但是,评估血管内治疗的试验得出了不同的功能结果,并且需要更好地定义亚组人群中血管内干预的效果。

目的

检查急性缺血性脑卒中患者中机械取栓血管内介入治疗与临床结局之间的关系。

数据来源

我们系统地检索了 MEDLINE、EMBASE、CINAHL、Google Scholar 和 Cochrane 图书馆,没有语言限制,检索时间截至 2015 年 8 月。

研究选择

符合条件的研究为机械取栓血管内治疗与标准药物治疗(包括静脉内使用组织型纤溶酶原激活剂[tPA])的随机临床试验。

数据提取和综合

独立评审员评估研究质量并提取数据。我们使用随机效应荟萃分析计算了所有结局的比值比(OR)和 95%置信区间(CI),并进行亚组和敏感性分析,以检查特定的影像学、患者、治疗或研究特征是否与改善的功能结局相关。使用 GRADE 方法评估所有结局的证据强度。

主要结局和测量指标

90 天改良 Rankin 量表(mRS)评分的有序改善、90 天功能性独立(mRS 评分,0-2)、24 小时血管造影再通、90 天内症状性颅内出血和 90 天全因死亡率。

结果

纳入了 8 项涉及 2423 例患者(平均[标准差]年龄,67.4[14.4]岁;1131 例[46.7%]为女性)的试验数据,其中 1313 例接受了血管内取栓治疗,1110 例接受了标准药物治疗联合 tPA。对这些试验的荟萃分析显示,血管内治疗与 mRS 评分的显著比例治疗获益相关(OR,1.56;95%CI,1.14-2.13;P = .005)。90 天功能性独立(mRS 评分,0-2)发生在血管内治疗组的 1293 例患者中的 557 例(44.6%;95%CI,36.6%-52.8%)和标准药物治疗组的 1094 例患者中的 351 例(31.8%;95%CI,24.6%-40.0%)(风险差异,12%;95%CI,3.8%-20.3%;OR,1.71;95%CI,1.18-2.49;P = .005)。与标准药物治疗相比,血管内取栓治疗与 24 小时更高的血管造影再通率显著相关(75.8% vs 34.1%;OR,6.49;95%CI,4.79-8.79;P < .001),但 90 天内症状性颅内出血发生率(70 例[5.7%] vs 53 例[5.1%];OR,1.12;95%CI,0.77-1.63;P = .56)或 90 天全因死亡率(218 例死亡[15.8%] vs 201 例死亡[17.8%];OR,0.87;95%CI,0.68-1.12;P = .27)无显著差异。

结论和相关性

在急性缺血性脑卒中患者中,与标准药物治疗联合 tPA 相比,机械取栓血管内治疗与改善的功能结局和更高的血管造影再通率相关,但 90 天内症状性颅内出血或全因死亡率无显著差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验